BridgeBio Pharma, Inc. Common Stock (BBIO) Financials
Key financial figures for BridgeBio Pharma, Inc. Common Stock (Q3 2026).
BridgeBio Q3 2026 revenue rose to $353.2M on $253.3M of Attruby net product revenue and a $75.0M Bayer milestone, narrowing the loss from operations to $11.6M. Total revenues, net were $353.2M versus $120.7M a year earlier, vs FMP estimate of $293.5M; EPS of $(0.42) vs FMP estimate of $(0.54). Attruby net product revenue was $253.3M, up about $31M sequentially from $222.4M and up from $108.1M a year ago. License and services revenue included a one-time $75.0M BEYONTTRA sales milestone from Bayer; loss from operations narrowed to $11.6M from $145.2M. Cash, cash equivalents and marketable securities were $1.54B at September 30, 2026, after the preferred equity financing and a 2033 notes issuance. Figures are for Q3 2026, as BridgeBio Pharma, Inc. reported them.
- Revenue
- $353M
- Net Income
- -$57M
- EPS
- $-0.42
- Total Assets
- $2.2B
- Operating Cash Flow
- -$44M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $353M | -$57M | -$0.42 | -3.3% | -$44M |
| Q2 FY2026 | $244M | -$152M | -$0.78 | -43.94% | -$72M |
| Q1 FY2026 | $195M | -$164M | -$0.84 | -54.47% | -$197M |
| Q4 FY2025 | $154M | -$197M | -$1.00 | -120.14% | -$61M |
| Q3 FY2025 | $121M | -$183M | -$0.95 | -120.3% | -$110M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $502M | -$729M | -$3.78 | -113.35% | -$447M |
| FY2024 | $222M | -$536M | -$2.88 | -267.22% | -$522M |
| FY2023 | $9M | -$643M | -$3.95 | -6528.75% | -$529M |
Frequently asked questions
What was BridgeBio Pharma, Inc.'s revenue last quarter?
BridgeBio Pharma, Inc. reported revenue of $353.2 million for Q3 FY2026, up 192.6% from the same period a year earlier.
Is BridgeBio Pharma, Inc. profitable?
Not in its most recent reported period. BridgeBio Pharma, Inc. reported a net loss of $56.7 million for Q3 FY2026, a net margin of -16.06% on revenue.
How has BridgeBio Pharma, Inc.'s margin trended?
Operating margin was -3.3% in Q3 FY2026, compared with -120.3% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did BridgeBio Pharma, Inc. generate?
BridgeBio Pharma, Inc. generated free cash flow of -$44.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for BridgeBio Pharma, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.